Scott Tozier
Analyst · Jeff Zekauskas with JPMorgan
Thanks, Kent, and good morning, everyone. I'll begin on Slide 7. We generated net sales of $774 million during the second quarter, which is a slight increase from the same period last year, driven by stronger sales from our Lithium and Bromine segment. Higher sales, as well as strong operating margins resulted in an adjusted EBITDA of $195 million, which was 5% higher year-over-year. GAAP net income of $425 million, includes an after-tax gain of $332 million related to the divestiture of our FCS business to W.R. Grace. Adjusted EPS, which excludes the gain on FCS was $0.89 for the quarter, up 4% from the prior year. Let's turn to Slide 8 for a look at adjusted EBITDA by business. Excluding FCS, second quarter adjusted EBITDA increased by 13% or $22 million compared to the prior year. Higher adjusted EBITDA for lithium and bromine was partially offset by higher corporate costs related to incentive compensation and foreign exchange movements. Lithium's adjusted EBITDA increased by $19 million excluding FX compared to last year, primarily driven by higher volumes as customers under long-term agreements continued to pull orders forward, and we shipped higher spodumene volumes from our Talison joint venture. Adjusted EBITDA for bromine increased by $16 million due to higher volumes and pricing. End market demand continues to be very strong. Following the winter storms experienced in Q1, we have very limited excess capacity or inventory to meet that additional demand. Catalysts' adjusted EBITDA declined just $1 million from the previous year. CFT volumes were down due to shipment timing. FCC continued to be impacted by a change in the order patterns from a large North American customer, although the FCC demand trend was generally higher. This was partially offset by excellent PCS results, which benefited from a favorable customer mix. Slide 9 highlights the company's financial strength. Since the beginning of the year, we have taken significant steps to strengthen our balance sheet. The strategic decision to divest our FCS business added cash proceeds to the balance sheet and reduced our leverage ratio to 1.5 times. That transaction further demonstrates our ability to drive value by prudently managing our asset portfolio. Our strong balance sheet and investment-grade credit rating gives us the financial flexibility we need to accelerate profitable growth and continue to provide a growing dividend. Turning to Slide 10, I'll walk you through the updates to our guidance that Kent mentioned earlier, and there are several key changes from our previous guidance. First, higher net sales guidance reflects higher lithium sales volumes and improving catalyst trends offset by our lower bromine outlook. Adjusted EBITDA guidance is the same, reflecting higher net sales, offset by higher corporate costs and foreign exchange expense. Guidance on adjusted diluted EPS and net cash from operations is improving from an expected reduction in interest expense and tax rate. The timing of working capital changes is also expected to benefit net cash from operations. And finally, we see capital expenditures trending toward the high end of our previous $850 million to $950 million range based on the tight labor markets in Western Australia, as Kent discussed. In the far right column, pro forma revised guidance ranges are adjusted for the sale of our FCS business on June 1st this year removing the guidance on FCS for the rest of the year. I'm turning to Slide 11 for a more detail on the GBUs outlook. Adjusted EBITDA for lithium is expected to increase by 10% to 15% over last year, an improvement from our previous outlook. Lithium volume growth is expected to be in the mid-teens on a percentage basis, mostly due to higher tolling volumes, as well as the restart of North American plants at the beginning of the year and improvements in plant productivity. Our pricing outlook is unchanged. We continue to expect average realized pricing to increase sequentially over the second half of the year, but to remain roughly flat compared to full year 2020. We also continue to expect margins to remain below 35%, owing to higher costs related to project start-ups and incremental tolling costs. Margin should improve, as the plants ramp up commercial sales volumes. Our outlook for Catalysts hasn't changed since the first quarter report with adjusted EBITDA anticipated to be lower by 30% to 40%. However, we are more optimistic, as fuel markets continued to improve globally. Lower year-over-year results are primarily related to the impact of the U.S. Gulf Coast, winter storm in the first quarter and the ongoing impact from the change in customer order patterns in North America. Finally for bromine, we now expect mid-single digit year-over-year growth in adjusted EBITDA, which is down from our previous outlook due to a force majeure declaration from our chlorine supplier in the U.S. Like many industrial companies, we are experiencing increased costs and supply disruptions for raw materials, but it is partially offset by price and productivity improvement. Results are expected to be lower in the second half, as production is constrained due to the chlorine shortage. We are accelerating our expansion plans in bromine. However, we have been unable to take advantage of this new capacity yet due to the chlorine disruption. Looking ahead to 2022, we expect sales and EBITDA increases for all three businesses, Lithium results are expected to improve on the higher volumes, as the new plants ramp up, Bromine results are expected to rebound from short-term supply chain disruptions and the winter storm impacts and Catalysts results are expected to rebound strongly from 2021 levels assuming continued improvements in global transportation fuel demand. And with that, I'll hand it back to Kent.